autism

Dr. M’s Women and Children First Podcast #119: Judy Van de Water, PhD –Maternal Autoantibodies and Autism

Welcome to Dr. M’s Women and Children First Podcast, where we explore the science, stories, and ideas that are changing how we understand the health of women and children—with a particular focus on how the earliest environments of life can shape health for decades to come.

Today we are going deep into one of those earliest environments: the immune conversation between a mother and her developing baby.

My guest is Dr. Judy Van de Water, an internationally recognized immunologist whose work has helped reshape our understanding of the relationship between maternal immune function, pregnancy, and neurodevelopment.

Dr. Van de Water received her Bachelor of Science in Biological Sciences from the University of California, Davis, in 1978, followed by her PhD in Immunology from UC Davis in 1988. She went on to build her career in clinical immunology and immunopathology and joined the UC Davis Department of Internal Medicine faculty in 1999. She subsequently became part of the newly established UC Davis MIND Institute, where her research increasingly focused on the immunobiology of autism and other neurodevelopmental disorders.

Her laboratory has spent decades investigating a fascinating question:

What happens when the maternal immune system interacts differently with the developing fetal brain?

That work has included the study of maternal cytokines and chemokines, immune dysregulation during pregnancy, environmental influences on immune function, and—perhaps most notably—the discovery and characterization of specific maternal autoantibodies that recognize proteins important to fetal brain development.

This research ultimately helped define what is now known as Maternal Autoantibody-Related Autism, or MAR autism—a biologically defined subtype of autism associated with specific patterns of maternal autoantibodies.

And I think her work raises a much larger question.

What if autism is not one biological condition at all?

What if the behavioral diagnosis we call autism represents a final common pathway reached through multiple biological routes—genetic, metabolic, environmental, inflammatory, immunologic, or some combination of them?

If that is true, identifying those biological subtypes becomes incredibly important.

Because once we understand mechanism, we can begin asking better questions about risk, prediction, prevention, and ultimately more precise care.

Today we’ll talk about how these maternal autoantibodies were discovered, why they develop in some women, what the animal and human studies tell us about causality, the science behind MAR autism and MARAbio, and perhaps the biggest question of all:

If we can identify a biological risk pathway before a child is born, what do we do with that information?

Enjoy,

Dr. M

 

Dr. M’s SPA Newsletter Volume 16 Issue 18 – Autism and Microbiomes

Autism and Diagnosis

Metabolites and Phenotypes

In a brand new paper entitled. “Elevated Microbially-Derived Metabolites in Autism: A Possible Diagnostic Screening Test for a Distinct ASD Phenotype,” Dr. Flynn and colleagues investigated whether specific urinary metabolites produced by intestinal microbes could serve as predictive biomarkers for autism spectrum disorder. The study proposes that a large subset of children with autism may represent a biologically distinct phenotype characterized by markedly elevated microbial metabolites, which the authors term ASD-MDM (Autism Spectrum Disorder associated with Microbially-Derived Metabolites).

The investigators analyzed urine samples from 52 children with ASD and 47 typically developing (TD) controls, ages 2–11 years. They measured microbial metabolites derived primarily from phenylalanine metabolism, tryptophan metabolism, and yeast metabolism. These were chosen because decades of autism, microbiome, and metabolic research have repeatedly implicated abnormalities in microbial metabolism of aromatic amino acids, especially phenylalanine and tryptophan, along with evidence of elevated fungal/yeast metabolites in subsets of children with ASD.

The findings were striking. Children with ASD demonstrated significantly higher concentrations of many microbial metabolites than controls. Some metabolites were elevated by hundreds to thousands of percent, and in certain children concentrations were reported to be 100–1000 times higher than the highest levels observed in any control participant. Twenty-three of twenty-four measured microbial metabolites were higher in ASD participants. Ninety percent of the ASD participants (45 of 50) had one or more extremely elevated MDMs. Particularly notable were elevations in compounds related to p-cresol, p-cresol sulfate, phenylacetylglutamine, indole derivatives, and arabinitol, suggesting abnormalities in microbial metabolism involving aromatic amino acids and yeast overgrowth…. Also, Inflammation and Allergy.

Enjoy,
Dr. M

Dr. M’s Women and Children First Podcast #101: Sandy Newmark, MD; Elisa Song, MD; Leslie Stone, MD – Autism Etiology?

Today’s conversation takes us upstream—to the source—of one of the most pressing and emotionally charged topics in modern pediatrics: the rise in autism spectrum disorders. Autism rates have continued to climb in 2025, but what if much of what we call “the epidemic” isn’t simply genetics or better diagnosis, but a reflection of deeper biological, environmental, and developmental changes affecting the human organism before birth?

To explore this critical question, I’m joined by three extraordinary clinicians who have dedicated their lives to understanding the roots of children’s health and disease.

Dr. Sandy Newmark, Clinical Professor of Pediatrics at the Osher Center for Integrative Medicine at UCSF, has spent the past two decades at the intersection of conventional and integrative medicine—focusing specifically on children with autism and ADHD. His approach blends deep compassion with scientific rigor, examining how nutrition, toxins, inflammation, and the microbiome shape the developing brain.

Dr. Elisa Song, Stanford-, NYU-, and UCSF-trained integrative pediatrician and author of Healthy Kids, Happy Kids, is one of the leading global voices in pediatric functional medicine. As founder and Chief Medical Officer of Healthy Kids Happy Kids and Tiny Health, she’s pioneering microbiome-centered strategies to reverse chronic disease in children and reshape how we think about wellness from the inside out.

Dr. Leslie Stone, family physician, obstetrician, and co-founder of GrowBabyHealth.com, brings a lifetime of experience delivering and caring for over 5,000 babies. Her groundbreaking work in the science of Developmental Origins of Health and Disease—the DOHaD model—shows how what happens before and during pregnancy programs a child’s long-term health, resilience, and risk for conditions like autism.

Together, we’ll discuss the emerging evidence that the autism epidemic is not a mystery of genetics alone, but a story written in inflammation, metabolic disruption, environmental exposures, and the developmental stressors of modern life. We’ll explore how integrative and functional medicine are reframing prevention—not just treatment—and what it will take to truly turn the tide for the next generation.

This is a conversation about hope, science, and the possibility of rewriting the future—one mother, one child, and one generation at a time.

Dr. M’s Women and Children First Podcast #100 Wayne Koontz, MD – Vaccines and Disease over 50 years

Today on Dr. M’s Women and Children First Podcast, we welcome Dr. Wayne Koontz, a founding partner at Salisbury Pediatric Associates in Salisbury North Carolina, where he has spent over 5 decades caring for generations of families with compassion, wisdom, and a deep commitment to community health.

Dr. Koontz earned his Undergraduate degree and his Doctor of Medicine from Wake Forest University, where his early love of science and service began to take shape. He went on to complete his pediatric residency at Dallas Children’s Medical Center, part of the University of Texas Southwestern Medical School, where he received outstanding training in both academic and clinical pediatrics.

As one of the founding physicians at Salisbury Pediatrics, Dr. Koontz helped to build a model of child-centered, family-oriented care that has served the Rowan County. His commitment to children’s well-being extends beyond the clinic, reflecting a lifelong dedication to preventive medicine, developmental health, and the nurturing of strong physician–family relationships.

It’s an honor to have Dr. Koontz with us today to share his clinical insights as they relate to infection and vaccination from a longevity based pediatric career. Dr. Koontz has a unique perspective to share as his 50 plus years of experience cover the prevaccine infectious disease based practice of pediatric medicine all the way to the current vaccine centric and reduced infectious disease burden reality. That is a timeline worthy of exploration.

So lets explore.

Dr. M

Dr. M’s SPA Newsletter Volume 15 Issue 22/23/24 – Acetaminophen and Autism

Review Part III – after the Attia Podcast

After completing the interview with Dr. William Parker and now listening to Peter Attia’s analysis, let us look again at this question. I repeat that the initial question has not changed for me. The first and most fundamental question to ask is this: What is the true value of acetaminophen in health compared with the potential risk if the associated findings are indeed correct?

My response to this question has been altered by the analysis so far.

I love this from Dr. Attia: “Some people might be wondering, why did you just take so long to explain all this to us? Why don’t you just give us the answer? I just want the sound bite, man

Peter’s reply, “If you just want sound bites, you’re never going to learn.”

Honestly, if you just want sound bites, this isn’t the podcast for you. But if you actually want to be able to learn to think for yourself, then that’s what we’re here to do. And that’s the reason we killed ourselves over the past week to put together the most thorough gathering of all the data we could find and the most intense night-weekend analysis possible. “

I agree! I believe that the science and data are key. So here goes – round three!…..

Dr. M

 

Dr. M’s Women and Children First Podcast #98 William Parker, PhD – Acetaminophen and Autism – What Do We Know in 2025?

Welcome to Dr. M’s Women & Children First Podcast, where we engage with pioneering voices at the intersection of science, healthcare, and the well-being of families.

Today, I’m honored to introduce Dr. William Parker, PhD. Dr. Parker is perhaps best known for discovering the function of the human appendix, but his contributions to science extend far beyond that single discovery. He studied biology and chemistry as an undergraduate before earning his PhD in Chemistry from the University of Nebraska–Lincoln in 1992. Since the 1980s, he has conducted innovative research, publishing more than 150 peer-reviewed articles that span immune function, microbiome science, and human health.

Dr. Parker was the first to compare immune systems in wild animals with those of their laboratory counterparts, and among the first to conclude that changes in the human “biota”, the symbiotic organisms living within us, brought on by modern society can contribute to depression and anxiety. After nearly three decades at Duke University, where he served as associate professor and research leader, he founded WPLab, Inc., a nonprofit dedicated to understanding and educating about the causes of chronic inflammatory diseases in high-income societies.

Currently a visiting scholar at the University of North Carolina, Dr. Parker collaborates widely with colleagues from Duke University, University of Montreal, Czech Academy of Sciences, University of Groningen, University of Colorado Boulder, and scientists across the pharmaceutical industry.

In recent years, he has turned his attention to a provocative and urgent question: the potential links between early acetaminophen exposure and autism spectrum outcomes. His current work combines mechanistic and epidemiologic approaches to explore how acetaminophen’s effects on human physiology at critical stages of development might influence neurodevelopment.

In our conversation, we’ll explore:

  • The evidence and hypotheses behind acetaminophen’s potential role in autism risk
  • What families and clinicians should know: what’s plausible, what remains speculative, and where research is heading next

I’m thrilled to share this episode with Dr. Parker, whose intellectual curiosity, scientific rigor, and courage to ask difficult questions embody the spirit of this show.

Dr. M

Dr. M’s SPA Newsletter Volume 15 Issue 15

Systemic Maternal Inflammation and Neurodevelopment: The Role of IL-6 and IFN-γ in Autism Spectrum Disorder

I just returned from Estes Park, Colorado where I presented a lecture on the Growing Brain/Mind – a tour through the underpinnings of childhood neurological changes that we call Autism. The timing is perfect for this article to be written.

In an era when chronic disease in children is rising at an unprecedented pace, the search for root causes must include an honest inquiry into the conditions present during fetal development. The review article by Majerczyk and colleagues, Systemic Maternal Inflammation Promotes ASD via IL-6 and IFN-γ, brings forward a critical piece in this puzzle that I began to explore a few years ago when writing a book. It connects the dots between maternal immune dysregulation and long-term neurodevelopmental outcomes, specifically autism spectrum disorder (ASD). Through a synthesis of clinical data and animal research, the authors make a compelling case for the centrality of two inflammatory messengers, interleukin-6 (IL-6) and interferon-gamma (IFN-γ), in shaping fetal brain development during gestational stress. The key words here being GESTATIONAL STRESS, the recurring scientific theme for ASD development, not vaccines… and some literature reviews.

Dr. M